We are live on ! Find out more
NMTR

9 Meters Biopharma
NMTR

Delisted

NMTR was delisted on the 25th of July, 2023.

Back to rankings

104 hedge funds and large institutions have $76.6M invested in 9 Meters Biopharma in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 33 increasing their positions, 27 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more call options, than puts

Call options by funds: $1.48M | Put options by funds: $1.2M

22% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 27

1% less funds holding

Funds holding: 105 → 104 (-1)

7% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 14

19% less capital invested

Capital invested by funds: $94.2M → $76.6M (-$17.6M)

Holders
104
Holders Change
-1
Holders Change %
-0.95%
% of All Funds
1.6%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
13
Increased
33
Reduced
27
Closed
14
Calls
$1.48M
Puts
$1.2M
Net Calls
+$271K
Net Calls Change
+$1.03M

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$1.91M
2
BlackRock
BlackRock
New York
+$669K
3
GTC
Ghost Tree Capital
New York
+$559K
4
GCP
GSA Capital Partners
United Kingdom
+$539K
5
Two Sigma Investments
Two Sigma Investments
New York
+$354K

Top Sellers

Rank Fund Capital Flow
1
Deutsche Bank
Deutsche Bank
Germany
-$1.04M
2
Millennium Management
Millennium Management
New York
-$646K
3
CIP
Chartwell Investment Partners
Pennsylvania
-$619K
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$472K
5
PAM
Panagora Asset Management
Massachusetts
-$411K
Name Holding Trade Value Shares
Change 		Change in
Stake
KIA
76
KCM Investment Advisors
California
$15K – – –
T. Rowe Price Associates
77
T. Rowe Price Associates
Maryland
$14K -$6.15K -275 -28%
Brown Advisory
78
Brown Advisory
Maryland
$14K – – –
CAPTRUST Financial Advisors
79
CAPTRUST Financial Advisors
North Carolina
$13K -$18.9K -845 -57%
RJA
80
Raymond James & Associates
Florida
$13K – – –
National Bank of Canada
81
National Bank of Canada
Quebec, Canada
$13K +$14.5K +650 New
HF
82
HRT Financial
New York
$13K +$14.9K +664 New
TRCT
83
Tower Research Capital (TRC)
New York
$12K -$1.61K -72 -11%
Squarepoint
84
Squarepoint
New York
$12K -$649 -29 -4%
Mackenzie Financial
85
Mackenzie Financial
Ontario, Canada
$12K – – –
SIC
86
Sterling Investment Counsel
New York
$12K +$14K +627 New
SXL
87
Summit X LLC
Missouri
$11K -$3.92K -175 -23%
X
88
Xponance
Pennsylvania
$11K +$268 +12 +2%
CIC
89
Carnegie Investment Counsel
Ohio
$10K – – –
GA
90
Gateway Advisory
New Jersey
$10K – – –
IWM
91
IHT Wealth Management
Illinois
$10K – – –
PAG
92
Private Advisor Group
New Jersey
$10K – – –
SCP
93
Sandhill Capital Partners
New York
$10K – – –
WS
94
Wedbush Securities
California
$10K – – –
TAM
95
Tocqueville Asset Management
New York
$10K +$11.4K +510 New
IFG
96
Independent Financial Group
California
$9.79K – – –
CA
97
CoreCap Advisors
Michigan
$6K +$6.73K +301 New
HFM
98
Hartford Financial Management
Connecticut
$4K – – –
PNC Financial Services Group
99
PNC Financial Services Group
Pennsylvania
$3K – – –
CG
100
Cutler Group
California
$2K -$1.34K -60 -30%
1 2 3
4
5

NMTR Hedge Fund Activity: Q4 2021 in Review

104 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in 9 Meters Biopharma (NMTR) for Q4 2021, worth a combined $76.6M — down 19% from $94.2M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of NMTR and 13 opened new positions — a net loss of 1 holder — while 27 trimmed existing stakes and 33 added.

The largest buyer was OrbiMed, adding an estimated $1.91M. The largest seller was Deutsche Bank, cutting an estimated $1.04M.

  • 104 institutional investors held 9 Meters Biopharma (NMTR) as of Q4 2021, down from 105 in Q3 2021.
  • Funds reported $76.6M of 9 Meters Biopharma stock for Q4 2021, down 19% quarter-over-quarter.
  • 13 funds opened new 9 Meters Biopharma positions in Q4 2021 and 14 closed out, a net change of -1 holder.
  • The largest 9 Meters Biopharma buyer in Q4 2021 was OrbiMed, an estimated $1.91M added.
  • The largest 9 Meters Biopharma seller in Q4 2021 was Deutsche Bank, an estimated $1.04M sold.

Based on aggregated 13F filings for Q4 2021.